Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted by Type & End-User The global artificial pancreas market will witness a robust CAGR of 8.53%, valued at $299.01 million in 2021, expected to appreciate and reach $624.64 million by 2030, confirms Strategic Market Research. The Artificial Pancreas is also widely known as the ‘Closed-Loop Control System which is an ‘All-In-One’ diabetes management system that efficiently tracks blood glucose levels by implementing a continuous glucose monitor (CGM) and automatically delivers the hormone insulin during its utmost need through an insulin pump. The closed-loop artificial pancreas is composed of an externally worn insulin pump that communicates wirelessly with the CGM. Pancreatitis (inflammation of the pancreas) is one of the major causes of the rise in mortality rates worldwide. According to WHO, in 2019, nearly (10-30) % of the total deaths were caused due to acute and severe pancreatitis worldwide. However, the immense technological advancements in the artificial pancreas persist the potential of drastically improving the lives of patients suffering from Type 1 and Type 2 diabetes. In 2019, about 9.3% of the adults worldwide aged between (20-79) years were affected by Type 1 diabetes, along with 1.12 Mn children under the age of 20. In the United States, 1,87,000 people were diagnosed with Type 1 diabetes in 2019, making up about 8.21% of the total US population. In 2018, type 2 diabetes affected approximately 6.41% of the world population and 34.18 Mn people in the United States of America. All the above-mentioned statistics are expected to stimulate Global Artificial Pancreas Market growth throughout the forecasted period. COVID-19 Impact The COVID-19 pandemic outbreak is a worldwide public health emergency, which has considerably affected the overall enhancement rate of the market. This life-threatening pandemic has led to chronic pancreatitis among the patients, caused by an abrupt rise of pancreatic enzymes in the blood. Glucose control through an artificial pancreas on extracorporeal membrane oxygenation is the most sought and innovative technology introduced in the market. CGM (Continuous Glucose Monitoring) reduces the rate of exposure of patients and healthcare workers to COVID-19 and decreases the usage of personal protective equipment. Market Drivers: Growing number of diabetic patients The continuous rising prevalence of diabetic patients worldwide is the primary reason for boosting the overall growth rate of this market. According to WHO, in 2019, 1.5 Mn people worldwide died because of diabetes, and it severely affected approximately 463 Mn people. It is expected to increase up to 700 Mn by 2045. An immense increase in expenditure for R&D activities is also one of the main reasons for boosting the market growth. An increase in the requirement of the APDS, or Artificial Pancreas Device System market, is efficiently driving the overall market enhancement rate. APDS is booming, with an overall growth rate of 20.27%. Restraints - Adverse Outcomes of Reimbursement Policies and Higher Costs The higher cost associated with the overall installation process of the equipment and the unfavourable reimbursement policies is the major factors that are extensively obstructing the growth rate of this market. The overall installation cost of the artificial pancreas system ranges between USD 7000 to USD 8000. Opportunities - Rise in the Usage of Insulin Pumps, and CGM Systems Recent advancements in insulin pumps and CGM systems have increased the market's growth rate and are likely to boost its future enhancement prospects. Patients with Type 2 diabetes receive an immense benefit from wearing an artificial pancreas run by computer algorithms. There are huge expectations regarding this technique to gain an exponential growth rate in the future. Market Analysis Of Different Segments Covered in the Report Based on Type: Threshold Suspended Device System Non-Threshold Suspended Device System Control to Range System (CTR) Control to Target System (CTT) Based on End-User: Hospitals Clinics Homecare Ambulatory Surgical Centers (ASCs) Others Regional Coverage Analysis North America US Canada Mexico Rest of North America Europe France U.K Netherlands Switzerland Germany Finland Belgium Russia Italy Spain Turkey Rest of Europe Asia Pacific China Japan India South Korea Malaysia Australia Singapore Thailand Indonesia Philippines Rest of Asia-Pacific LAMEA Brazil Argentina Uruguay Saudi Arabia Rest of LAMEA The Threshold Suspended Device System dominated the market in 2017 with the highest overall market share of 71.58% due to its design and effectiveness in facilitating comprehensive & accurate colon examinations. The advanced technology & reliability of the system makes it a preferred choice for many medical facilities aiming to provide high-quality colonoscopy procedures. The CTT system is the fastest-growing segment and is expected to sprout at a CAGR of 37.75% throughout the forecasted period. Based on End-User, the ‘Hospitals’ segment significantly dominates the market as it contains some of the most efficiently planned referral networks for responding adequately to the population's health needs. According to the American Diabetes Association, the overall cost of diagnosed diabetes in 2017 was USD 327 Billion. (USD 237 Bn in direct medical costs and USD 90 Billion in productivity). Based on Regions, North America significantly dominated the overall market with the highest revenue and market share and will flourish its dominance over the projected period. The primary reason behind its prominence is its highly efficient levels of facilities, along with the advancement of various technologies in the healthcare sector. The leading players in this region are also fostering the growth of the market simultaneously. Artificial Pancreas Market Report Coverage Report Attribute Details Forecast Period 2020 - 2028 The market size value in 2020 USD 275.51 Million The revenue forecast in 2028 USD 460.2 Million Growth rate CAGR of approximately 8.53% The base year for estimation 2020 Historical data 2015 – 2019 Unit USD Billion, CAGR (2020 - 2028) Segmentation By Type, By Application, By Region By Type Threshold Suspended Device System, Non-Threshold Suspended Device System, Control to Range System (CTR), Control to Target System (CTT). By End-User Hospitals, Clinics, Homecare, Ambulatory Surgical Centers (ASCs), and Others. By Region North America, Europe, Asia-Pacific, LAMEA. Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Johnson & Johnson Services Inc., Medtronic, Admetsys, Insulet Corporation, Tandem Diabetes Care Inc, F. Hoffmann-La Roche Ltd, Beta Bionics Inc, Glooko Inc, Teladoc Health Inc, BIGFOOT BIOMEDICAL Inc., Verily Life Sciences LLC, Vertex Pharmaceuticals Incorporated, Dexcom, Diabeloop SA, ViaCyte Inc, JDRF, TypeZero Technologies, Inc, Dexcom Inc, Animas Corporation.. Pricing and purchase options Avail customized purchase options to meet your exact research needs. Artificial Pancreas Market Competitive Landscape Analysis A 360-degree competitive landscape analysis provides the most accurate details regarding the significant competitors prevailing in the market environment. The comparison is performed based on the total revenue generated, market potential, company overview, investment in R&D, market initiatives, global presence, production capacities, company financials, company strengths and weaknesses, production sites and facilities, etc. Johnson & Johnson Services Inc. Medtronic Admetsys Insulet Corporation Tandem Diabetes Care Inc F. Hoffmann-La Roche Ltd Beta Bionics Inc Glooko Inc Teladoc Health Inc BIGFOOT BIOMEDICAL Inc. Verily Life Sciences LLC Vertex Pharmaceuticals Incorporated Dexcom Diabeloop SA ViaCyte Inc JDRF TypeZero Technologies, Inc Dexcom Inc Animas Corporation Recent Developments In June 2024, the largest privately held independent Clinical Research Organization (CRO) and consultancy firm for medical devices, diagnostics, and biologics, MCRA, announced that it assisted CamDiab's artificial pancreas software, CamAPS FX, in receiving FDA clearance in the United States. In April 2024, NHS England (NHSE) is planning a world-first launch that will provide tens of thousands of type 1 diabetes patients with a life-changing 'artificial pancreas'. NHSE has awarded £2.5 million to regional health executives in order to determine which patients will benefit from Hybrid Closed Loop systems, after the technology underwent a successful test. Frequently Asked Question About This Report Who are the topmost industry players in the market? The top most and prominent industry players of the market are Medtronic, Johnson and Johnson Inc, Bigfoot Biomedical Inc, Dexcom, Insulet Corporation, Admetsys, etc. What are the top trends that are currently prevailing in the market? The top trends of the market include high technological advancements in insulin pumps and CGM systems, usage of computer algorithms to monitor the functioning of artificial pancreas, the introduction of smartphone technologies, etc. Which is the most dominant End User segment of the Indusrty? The Hospitals segment accounted for the leading End User segment of the market over the forecasted period. Which geographical region is dominating the market? North America is significantly dominating the market throughout the forecasted period of 2020-2028. What are the market that have been inculcated in this report? Based on Type, the market is sub-segmented into Threshold Suspended Device System, Non-Threshold Suspended Device System, Control to Range System (CTR), and Control to Target System (CTT). How big is the global artificial pancreas market? In 2020, the total dollar value of the global artificial pancreas market share was valued at USD 275.51 Mn, and is expected to reach up to USD 460.2 Mn by 2028. Which one is the most leading transplant type in the market? Mostly, the pancreas transplant is done to treat Type 1 diabetic patients. However, the most leading Type of transplant is Simultaneous pancreas-kidney transplant (SPK Transplant). Sources https://www.who.int/news-room/fact-sheets/detail/diabetes https://diabetes.org/about-us/statistics/cost-diabetes https://pubmed.ncbi.nlm.nih.gov/31518657/ https://news.virginia.edu/content/fda-approves-uva-developed-artificial-pancreas https://www.healthline.com/diabetesmine/bigfoot-unity-connected-diabetes-system Chapter 1. Introduction 1.1 Study Objectives 1.2 Market Definition Table 1 Inclusions and Exclusions 1.3 Study Scope 1.3.1 Markets Covered Figure 01: Market Segmentation 1.3.2 Geographic Scope Figure 02: Market Geography covered 1.3.3 Years Considered 1.4 Stakeholders Chapter 2. Research Methodology 2.1 Data Procurement 2.2 Paid Database 2.2.1 Secondary Data 2.2.1.1 Key Secondary sources 2.2.2 Primary Data 2.2.2.1 Primary sources 2.2.2.2 Key industry insights 2.2.2.3 Primary interviews with experts 2.2.2.4 Key primary respondent list 2.3 Market Size Estimation 2.4 Bottom-Up and Top-Down Approaches 2.4.1 Bottom-Up Approach 2.4.1.1 Approach for arriving at market size by bottom-up analysis Figure 03: Market: Bottom-Up Approach 2.4.2 Top-Down Approach 2.4.2.1 Approach for Capturing Market Size by Top-Down Analysis Figure 04: Market: Top-Down Approach 2.5 Market Breakdown and Data Triangulation Figure 05: Data Triangulation 2.6 Research Methodology 2.7 Risk Assessment Table 2: Risk Assessment Chapter 3. Executive Summary 3.1 Market: Post-Covid-19 Figure 06: Impact of Covid-19 on Market 3.1.1 Actual Scenario Figure 07: Realistic Scenario: Market, 2020–2028 (USD Million) 3.1.2 Pessimistic Scenario Figure 08: Pessimistic Scenario: Market, 2020–2028 (USD Million) 3.1.3 Optimistic Scenario Figure 09: Optimistic Scenario: Market, 2020–2028(USD Million) 3.1.4 Market Summary Figure 10: Threshold Suspended Device System to Witness Highest CAGR in Market, By Type, During Forecast Period Figure 11: Hospitals Higher CAGR in Market for Application Segment during Forecast Period Figure 12: North America to Account for Largest Share of Global Market In 2020 Chapter 4. Market Definitions 4.1 Market Segmentation Figure 13: Market Segmentation Chapter 5. Industry Outlook 5.1 Market Snapshot 5.2 Global Artificial Pancreas Market 5.2.1 Global Market, 2020 – 2028 (USD Million) 5.3 Regional Segment Analysis 5.3.1 Global Market, by region, 2020 - 2028 (USD Million) 5.4 Type Segment Analysis 5.4.1 Global Market, by Type, 2020 - 2028 (USD Million) 5.5 Application Segment Analysis 5.5.1 Global Market, By Application, 2020 - 2028 (USD Million) 5.6 Value Chain Analysis 5.7 Market Variable Analysis 5.7.1 Market Drivers Analysis 5.7.2 Market Restraints Analysis 5.8 Business Environment Analysis Tool 5.8.1 Market PEST analysis 5.18.2 Market Porter’s analysis 5.9 Penetration & Growth Prospect Mapping Chapter 6. Market Overview 6.1 Introduction 6.2 Market Dynamics Figure 14 Market: Drivers, Restraints, Opportunities, and Challenges 6.2.1 Drivers Figure 15 Market Drivers and Their Impact 6.2.2 Restraints Figure 16 Market Restraints and Their Impact 6.2.3 Opportunities Figure 17 Market Opportunities and Their Impact 6.2.4 Challenges Figure 18 Market Challenges and Their Impact 6.3 Impact of Covid-19 on Market 6.4 Value Chain Analysis Figure 19 Value Chain Analysis: Market 6.5 Ecosystem Figure 20 Market: Ecosystem Table 3 Market: Ecosystem Figure 21 Revenue Shift in Market 6.6 Patent Analysis Table 4 Number of Patents Registered in Market in USA in Last 9 Years Figure 22 Top 19 Companies with Highest No. of Patents in Last 9 Years Figure 23 No of Patents Granted Per Year, 2019–2020 Table 5 List of Global Patents in Market 6.7 Trade Analysis Figure 24 Import Data for Threshold Suspended Device System, By Country, 2016–2020 (USD Thousand) Table 6 Import Data for Non-Threshold Suspended Device System, By Country, 2016–2020 (USD Thousand) Figure 25 Import Data for Control to Range System (CTR), By Country, 2016–2020 (USD Thousand) Table 7 Import Data for Control to Target System (CTT), By Country, 2016–2020 (USD Thousand) Figure 26 Export Data for Threshold Suspended Device System, By Country, 2016–2020 (USD Thousand) Table 8 Export Data for Non-Threshold Suspended Device System, By Country, 2016–2020 (USD Thousand) Figure 27 Export Data for Control to Range System (CTR), By Country, 2016–2020 (USD Thousand) Table 9 Export Data for Control to Target System (CTT), By Country, 2016–2020 (USD Thousand) 6.8 Tariff Analysis 6.9 Case Study Analysis 6.10 Porter’s Five Forces Analysis Table 10 Market: Porter’s Five Forces Analysis, 2020 6.10.1 Threat of New Entrants 6.10.2 Threat of Substitutes 6.10.3 Bargaining Power of Buyers 6.10.4 Bargaining Power of Suppliers 6.10.5 Degree of Competition 6.11 Technology Analysis 6.11.1 Trends in Technology (2014-2020) 6.11.2 Trends in Technology (2021-2028) Table 11 Key Regulations: Market 6.12 Pricing Analysis 6.12.1 Average Price Trend Analysis (By region, By Countries) Chapter 7. Competitive & Vendor Landscape 7.1 Company Market Share Analysis Table 12: Key Players market share Figure 28: Key players market share of companies 7.2 Manufacturers Artificial Pancreas Manufacturing Sites, Area Served, Product Type 7.3 Market Competitive Situation and Trends 7.4 Manufacturers Mergers & Acquisitions, Expansion Plans Chapter 8. Global Artificial Pancreas Market: Type Segment Analysis 8.1 Introduction 8.2 Sales Volume & Revenue Analysis (2020-2028) Table 13 Market, By Type, 2021–2028 (USD Million) Figure 29 Market, By Type Figure 30 Threshold Suspended Device System Segment to Register Highest CAGR in Market During Forecast Period 8.3 Threshold Suspended Device System 8.3.1 Threshold Suspended Device System market, 2020 - 2028 (USD Million) Figure 31: Threshold Suspended Device System market, 2020 - 2028 (USD Million) 8.4 Non-Threshold Suspended Device System 8.4.1 Non-Threshold Suspended Device System market, 2020 - 2028 (USD Million) Figure 32: Non-Threshold Suspended Device System market, 2020 - 2028 (USD Million) 8.5 Control to Range System (CTR) 8.5.1 Control to Range System (CTR) market, 2020 - 2028 (USD Million) Figure 33: Control to Range System (CTR) market, 2020 - 2028 (USD Million) 8.6 Control to Target System (CTT) 8.6.1 Control to Target System (CTT) market, 2020 - 2028 (USD Million) Figure 34: Control to Target System (CTT) market, 2020 - 2028 (USD Million) Chapter 9. Global Market: Application Segment Analysis 9.1 Introduction 9.2 Sales Volume & Revenue Analysis (2020-2028) Table 14: Market, By Application, 2021–2028 (USD Million) Figure 35: Market, By Application, 2021–2028 (USD Million) Figure 36: Hospitals Segment to Register Highest CAGR in Market during Forecast Period 9.3 Hospitals 9.3.1 Hospitals market, 2020 - 2028 (USD Million) Figure 37: Hospitals market, 2020 - 2028 (USD Million) 9.4 Clinics 9.4.1 Clinics market, 2020 - 2028 (USD Million) Figure 38: Clinics market, 2020 - 2028 (USD Million) 9.5 Homecare 9.5.1 Homecare market, 2020 - 2028 (USD Million) Figure 39: Homecare market, 2020 - 2028 (USD Million) 9.6 Ambulatory Surgical Centers (ASCs) 9.6.1 Ambulatory Surgical Centers (ASCs) market, 2020 - 2028 (USD Million) Figure 40: Ambulatory Surgical Centers (ASCs) market, 2020 - 2028 (USD Million) 9.7 Others 9.7.1 Others market, 2020 - 2028 (USD Million) Figure 41: Others market, 2020 - 2028 (USD Million) Chapter 10. Global Market: Regional Outlook 10.1 North America Figure 42: North America Market, By Revenue Forecast (2020-2028) 10.1.1 North America Market, by country, 2020 - 2028 (USD Million) Table 15: North America Market, by Country, 2020-2028 Figure 43: North America Market 10.1.2 North America Market, by Type, 2020 - 2028 (USD Million) Table16: North America Market, by Type, 2020 - 2028 (USD Million) Figure 44: North America Market, by Type, 2020 - 2028 (USD Million) 10.1.3 North America Market, by Application, 2020 - 2028 (USD Million) Table 17: North America Market, by Application, 2020 - 2028 (USD Million) Figure 45: North America Market, by Application, 2020 - 2028 (USD Million) 10.1.4 U.S. 10.1.4.1 U.S. Market, by Type, 2020 - 2028 (USD Million) Figure 46: U.S. Market, by Type, 2020 - 2028 (USD Million) 10.1.4.2 U.S. Market, by Application, 2020 - 2028 (USD Million) Figure 47: U.S. Market, by Application, 2020 - 2028 (USD Million) 10.1.5 Canada 10.1.5.1 Canada Market, by Type, 2020 - 2028 (USD Million) Figure 48: Canada Market, by Type, 2020 - 2028 (USD Million) 10.1.5.2 Canada Market, by Application, 2020 - 2028 (USD Million) Figure 49: Canada Market, by Application, 2020 - 2028 (USD Million) Figure 50: Canada Market, by Application, 2020 - 2028 (USD Million) Figure 51: Canada Market, by Application, 2020 - 2028 (USD Million) 10.2 Europe Figure 52: Europe Market, By Revenue Forecast (2020-2028) 10.2.1 Europe Market, by country, 2020 - 2028 (USD Million) Table 18: Europe Market, by country, 2020 - 2028 (USD Million) Figure 53: Europe Market, by country, 2020 - 2028 (USD Million) 10.2.2 Europe Market, by Type, 2020 - 2028 (USD Million) Table 19: Europe Market, by Type, 2020 - 2028 (USD Million) Figure 54: Europe Market, by Type, 2020 - 2028 (USD Million) 10.2.3 Europe Market, by Application, 2020 - 2028 (USD Million) Table 20: Europe Market, by Application, 2020 - 2028 (USD Million) Figure 55: Europe Market, by Application, 2020 - 2028 (USD Million) 10.2.4 U.K. 10.2.4.1 U.K. Market, by Type, 2020 - 2028 (USD Million) Figure 56: U.K. Market, by Type, 2020 - 2028 (USD Million) 10.2.4.2 U.K. Market, by Application, 2020 - 2028 (USD Million) Figure 57: U.K. Market, by Application, 2020 - 2028 (USD Million) 10.2.5 Germany 10.2.5.1 Germany Market, by Type, 2020 - 2028 (USD Million) Figure 58: Germany Market, by Type, 2020 - 2028 (USD Million) 10.2.5.2 Germany Market, by Application, 2020 - 2028 (USD Million) Figure 59: Germany Market, by Application, 2020 - 2028 (USD Million) 10.2.6 France 10.2.6.1 France Market, by Type, 2020 - 2028 (USD Million) Figure 60: France Market, by Type, 2020 - 2028 (USD Million) 10.2.6.2 France Market, by Application, 2020 - 2028 (USD Million) Figure 61: France Market, by Application, 2020 - 2028 (USD Million) 10.2.7 Rest of Europe 10.2.7.1 Rest of Europe Market, by Type, 2020 - 2028 (USD Million) Figure 62: Rest of Europe Market, by Type, 2020 - 2028 (USD Million) 10.2.7.2 Rest of Europe Market, by Application, 2020 - 2028 (USD Million) Figure 63: Rest of Europe Market, by Application, 2020 - 2028 (USD Million) 10.3 Asia Pacific Figure 64: Asia Pacific Market, By Revenue Forecast (2020-2028) 10.3.1 Asia Pacific Market, by country, 2020 - 2028 (USD Million) Table 21: Asia Pacific Market, by country, 2020 - 2028 (USD Million) Figure 65: Asia Pacific Market, by country, 2020 - 2028 (USD Million) 10.3.2 Asia Pacific Market, by Type, 2020 - 2028 (USD Million) Table 22: Asia Pacific Market, by Type, 2020 - 2028 (USD Million) Figure 66: Asia Pacific Market, by Type, 2020 - 2028 (USD Million) 10.3.3 Asia Pacific Market, by Application, 2020 - 2028 (USD Million) Table 23: Asia Pacific Market, by Application, 2020 - 2028 (USD Million) Figure 67: Asia Pacific Market, by Application, 2020 - 2028 (USD Million) 10.3.4 China 10.3.4.1 China Market, by Type, 2020 - 2028 (USD Million) Figure 68: China Market, by Type, 2020 - 2028 (USD Million) 10.3.4.2 China Market, by Application, 2020 - 2028 (USD Million) Figure 69: China Market, by Application, 2020 - 2028 (USD Million) 10.3.5 India 10.3.5.1 India Market, by Type, 2020 - 2028 (USD Million) Figure 70: India Market, by Type, 2020 - 2028 (USD Million) 10.3.5.2 India Market, by Application, 2020 - 2028 (USD Million) Figure 71: India Market, by Application, 2020 - 2028 (USD Million) 10.3.6 Japan 10.3.6.1 Japan Market, by Type, 2020 - 2028 (USD Million) Figure 72: Japan Market, by Type, 2020 - 2028 (USD Million) 10.3.6.2 Japan Market, by Application, 2020 - 2028 (USD Million) Figure 73: Japan Market, by Application, 2020 - 2028 (USD Million) 10.3.7 South Korea 10.3.7.1 South Korea Market, by Type, 2020 - 2028 (USD Million) Figure 74: South Korea Market, by Type, 2020 - 2028 (USD Million) 10.3.7.2 South Korea Market, by Application, 2020 - 2028 (USD Million) Figure 75: South Korea Market, by Application, 2020 - 2028 (USD Million) 10.3.8 Rest of APAC 10.3.8.1 Rest of APAC Market, by Type, 2020 - 2028 (USD Million) Figure 76: Rest of APAC Market, by Type, 2020 - 2028 (USD Million) 10.3.8.2 Rest of APAC Market, by Application, 2020 - 2028 (USD Million) Figure 77: Rest of APAC Market, by Application, 2020 - 2028 (USD Million) 10.4 Latin America Figure 78: Latin America Market, By Revenue Forecast (2020-2028) 10.4.1 Latin America Market, by country, 2020 - 2028 (USD Million) Table 24: Latin America Market, by country, 2020 - 2028 (USD Million) Figure 79: Latin America Market, by country, 2020 - 2028 (USD Million) 10.4.2 Latin America Market, by Type, 2020 - 2028 (USD Million) Table 25: Latin America Market, by Type, 2020 - 2028 (USD Million) Figure 80: Latin America Market, by Type, 2020 - 2028 (USD Million) 10.4.3 Latin America Market, by Application, 2020 - 2028 (USD Million) Table 26: Latin America Market, by Application, 2020 - 2028 (USD Million) Figure 81: Latin America Market, by Application, 2020 - 2028 (USD Million) 10.4.4 Brazil 10.4.4.1 Brazil Market, by Type, 2020 - 2028 (USD Million) Figure 82: Brazil Market, by Type, 2020 - 2028 (USD Million) 10.4.4.2 Brazil Market, by Application, 2020 - 2028 (USD Million) Figure 83: Brazil Market, by Application, 2020 - 2028 (USD Million) 10.4.5 Mexico 10.4.5.1 Mexico Market, by Type, 2020 - 2028 (USD Million) Figure 84: Mexico Market, by Type, 2020 - 2028 (USD Million) 10.4.5 2 Mexico Market, by Application, 2020 - 2028 (USD Million) Figure 85: Mexico Market, by Application, 2020 - 2028 (USD Million) 10.4.6 Rest of the Latin America 10.4.6.1 Rest of the Latin America Market, by Type, 2020 - 2028 (USD Million) Figure 86: Rest of the Latin America Market, by Type, 2020 - 2028 (USD Million) 10.4.6.2 Rest of the Latin America Market, by Application, 2020 - 2028 (USD Million) Figure 87: Rest of the Latin America Market, by Application, 2020 - 2028 (USD Million) 10.5 MEA Figure 88: MEA Market, By Revenue Forecast (2020-2028) 10.5.1 MEA Market, by Type, 2020 - 2028 (USD Million) Figure 89: MEA Market, by Type, 2020 - 2028 (USD Million) 10.5.2 MEA Market, by Application, 2020 - 2028 (USD Million) Figure 90: MEA Market, by Application, 2020 - 2028 (USD Million) Chapter 11. Competitive Landscape 11.1 Johnson & Johnson Services Inc. 11.1.1 Company overview 11.1.2 Financial performance 11.1.3 Product Portfolio Analysis 11.1.4 Business Strategy & Recent Development 11.2 Medtronic. 11.2.1 Company overview 11.2.2 Financial performance 11.2.3 Product Portfolio Analysis 11.2.4 Business Strategy & Recent Development 11.3 Admetsys. 11.3.1 Company overview 11.3.2 Financial performance 11.3.3 Product Portfolio Analysis 11.3.4 Business Strategy & Recent Development 11.4 Insulet Corporation. 11.4.1 Company overview 11.4.2 Financial performance 11.4.3 Product Portfolio Analysis 11.4.4 Business Strategy & Recent Development 11.5 Tandem Diabetes Care Inc. 11.5.1 Company overview 11.5.2 Financial performance 11.5.3 Product Portfolio Analysis 11.5.4 Business Strategy & Recent Development 11.6 F. Hoffmann-La Roche Ltd. 11.6.1 Company overview 11.6.2 Financial performance 11.6.3 Product Portfolio Analysis 11.6.4 Business Strategy & Recent Development 11.7 Beta Bionics Inc. 11.7.1 Company overview 11.7.2 Financial performance 11.7.3 Product Portfolio Analysis 11.7.4 Business Strategy & Recent Development 11.8 Glooko Inc. 11.8.1 Company overview 11.8.2 Financial performance 11.8.3 Product Portfolio Analysis 11.8.4 Business Strategy & Recent Development 11.9 Teladoc Health Inc. 11.9.1 Company overview 11.9.2 Financial performance 11.9.3 Product Portfolio Analysis 11.9.4 Business Strategy & Recent Development 11.10 BIGFOOT BIOMEDICAL Inc. 11.10.1 Company overview 11.10.2 Financial performance 11.10.3 Product Portfolio Analysis 11.10.4 Business Strategy & Recent Development 11.11 Verily Life Sciences LLC. 11.11.1 Company overview 11.11.2 Financial performance 11.11.3 Product Portfolio Analysis 11.11.4 Business Strategy & Recent Development 11.12 Vertex Pharmaceuticals Incorporated. 11.12.1 Company overview 11.12.2 Financial performance 11.12.3 Product Portfolio Analysis 11.12.4 Business Strategy & Recent Development 11.13 Dexcom. 11.13.1 Company overview 11.13.2 Financial performance 11.13.3 Product Portfolio Analysis 11.13.4 Business Strategy & Recent Development 11.14 Diabeloop SA. 11.14.1 Company overview 11.14.2 Financial performance 11.14.3 Product Portfolio Analysis 11.14.4 Business Strategy & Recent Development 11.15 ViaCyte Inc. 11.15.1 Company overview 11.15.2 Financial performance 11.15.3 Product Portfolio Analysis 11.15.4 Business Strategy & Recent Development 11.16 JDRF. 11.16.1 Company overview 11.16.2 Financial performance 11.16.3 Product Portfolio Analysis 11.16.4 Business Strategy & Recent Development 11.17 TypeZero Technologies, Inc. 11.17.1 Company overview 11.17.2 Financial performance 11.17.3 Product Portfolio Analysis 11.17.4 Business Strategy & Recent Development 11.18 Dexcom Inc. 11.18.1 Company overview 11.18.2 Financial performance 11.18.3 Product Portfolio Analysis 11.18.4 Business Strategy & Recent Development 11.19 Animas Corporation. 11.19.1 Company overview 11.19.2 Financial performance 11.19.3 Product Portfolio Analysis 11.19.4 Business Strategy & Recent Development